Oxaliplatin Injection, Solution
Product Images NDC 68083-177

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 68083-177). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxaliplatin Spl 10ml Carton Label

Oxaliplatin Injection, USP 50 mg/10 mL (5 mg/mL) single-dose vial packaging label for intravenous use. The label specifies the product as a cytotoxic agent, sterile aqueous solution, preservative-free, with storage instructions and manufacturing details by Gland Pharma Limited, India. The package includes warnings against mixing with sodium chloride-containing solutions.*

FDA Label Image

Oxaliplatin Spl 20ml Carton Label

Packaging label for Oxaliplatin Injection, USP 100 mg/20 mL (5 mg/mL) intravenous injection solution. The label includes warnings such as 'Cytotoxic Agent' and 'DO NOT MIX OR ADD TO SODIUM CHLORIDE/CHLORIDE-CONTAINING SOLUTIONS.' It is sterile, preservative-free, and meant for single-dose use. Manufactured by Gland Pharma Limited, India.*

FDA Label Image

Oxaliplatin Spl 40ml Carton Label

Packaging label for Oxaliplatin Injection, USP 200 mg/40 mL (5 mg/mL) solution for intravenous use, labeled as a cytotoxic agent. Manufactured by Gland Pharma Limited, the label includes storage instructions, cautions against mixing with sodium chloride or chloride-containing solutions, and indicates a single-dose 40 mL vial. Barcode and lot/expiration date fields are present.*

FDA Label Image

Oxaliplatin Spl Figure 01

A Kaplan-Meier survival curve graph showing Disease-Free Survival (DFS) probability over time in months. The graph compares two arms, FOLFOX4 and LV5FU2, with number of events and patients at risk indicated. A hazard ratio with confidence interval and p-value from a stratified logrank test is displayed.*

FDA Label Image

Oxaliplatin Spl Figure 02

A Kaplan-Meier survival curve graph displaying Disease-Free Survival (DFS) probability over time in months for two treatment arms: FOLFOX4 compared to DUKES C, and LV5FU2 compared to DUKES C. The graph includes a hazard ratio with 95% confidence interval and a p-value from a Logrank test for Stage III patients.*

FDA Label Image

Oxaliplatin Spl Figure 03

A survival curve chart showing the percentage of patients surviving over 24 months for three treatment groups: Oxaliplatin plus 5-FU/LV, Oxaliplatin plus irinotecan, and Irinotecan plus 5-FU/LV. The chart includes median survival times for each group and a p-value indicating statistical significance.*

FDA Label Image

Oxaliplatin Spl Structure

Chemical structure of oxaliplatin, showing a platinum atom centrally bonded to a cyclohexane diamine and an oxalate ligand.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.